Novo Nordisk Investigational Site
San Antonio, Texas, 78229, United States
NCT Number: NCT00127296
This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.
Looking for future studies?
Notify Me40 year–99 year
All sexes
Interventional
Phase 1
San Antonio, Texas, 78229, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Novo Nordisk A/S
Industry
Comparison of the Accuracy and Precision of NovoLog® Mix 70/30 FlexPen® to Vial and Syringe in Patients With Type 2 Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00773279
Autoimmune Diseases, Delivery Systems
Burlingame, California, United States
View Trial DetailsNCT01680328
Autoimmune Diseases, Delivery Systems
Neuss, Germany
View Trial DetailsNCT00871416
Autoimmune Diseases, Delivery Systems
Aarhus, Denmark
View Trial DetailsNCT00343343
Autoimmune Diseases, Delivery Systems
Aalborg, Denmark
View Trial Details